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CLINICAL COMMUNICATION TO THE EDITOR

Narcotic-induced Pain
To the Editor:
A man in his 40s with a history of diabetes mellitus type
1, hypertension, neuropathy on chronic opioids, and endstage renal disease was referred to our hospital for management of chronic abdominal pain, nausea, vomiting, and
anorexia of 2 years duration.
His symptoms had started in 2012 when he was admitted
for severe abdominal pain, nausea, vomiting, and anorexia
for 2 months. During that admission, multiple investigations
were done, including upper and lower gastrointestinal
endoscopy, nuclear gastric emptying scan, and computed
tomography scan of the abdomen; these investigations did
not show any abnormality. The patient was diagnosed with
“possible gastroparesis” based on clinical suspicion and
absence of other gastrointestinal disorders. He was subsequently discharged from the hospital after partial improvement in his symptoms.
During the next 2 years, he was admitted frequently to
multiple hospitals for the same symptoms. He was treated
with high doses of opioids. He also was treated with botulinum toxin injections to the pylorus, which failed to relieve
the pain. He also underwent repeated laboratory and imaging tests, which did not reveal any abnormalities. During
this period, his opioid dose was steadily escalated to 100 mg/h
of transdermal fentanyl and 2 mg oral hydromorphone every
4 hours.
He was admitted to our hospital in 2014 for worsening
abdominal pain, nausea, vomiting, and severe anorexia. He
was treated with opioids and antiemetics, with modest
decrease in symptoms. These ﬁndings in the presence of
normal nuclear gastric emptying scans along with other
normal laboratory and imaging studies led us to question the
diagnosis of gastroparesis.
Narcotic bowel syndrome was suspected. His opioid
dose was tapered slowly and subcutaneous methylnaltrexone was administered, which led to dramatic improvement
in his symptoms. He also was treated with clonidine,
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olanzapine, and gabapentin during the hospitalization, for
management of withdrawal symptoms. His symptoms
completely subsided, and he could tolerate oral food. He
made a remarkable recovery with complete resolution of
symptoms.

DISCUSSION
Narcotic bowel syndrome is a common side effect of opioids
and affects 6% of long-term users. It is frequently underrecognized and can have devastating consequences,
including extended hospitalizations, emergency department
visits, maladaptive physician-patient interaction, and loss of
work and disability.1
Narcotic bowel syndrome is an opioid-induced hyperalgesic state mediated via the central nervous system and is
distinct from the deleterious effects of opioids that are
mediated peripherally.2 Proinﬂammatory cytokines released
from glial cells in the dorsal horn of the spinal cord cause
induction of pain in narcotic bowel syndrome.2,3
Narcotic bowel syndrome is essentially a clinical diagnosis. It is marked by recurring abdominal pain while
being treated with opioids and worsening or incomplete
resolution of pain with escalation of the narcotic dose.
Over time, the frequency and severity of pain episodes
increase. Narcotic bowel syndrome should be distinguished
from other gastrointestinal, gynecological, and functional
disorders.1,2
A three-phase treatment algorithm has been recommended.2,4 The ﬁrst phase involves changing short-acting
opioids to long-acting opioids and starting nonopioid pain
medications, the second phase involves 10%-33% daily
reduction in opioid dose as an inpatient, and the third phase
starts after opioid withdrawal and involves psychological
and social support. Antidepressants including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants have been
shown to be effective in pain management. Other psychotropic agents including mood stabilizers, atypical antipsychotics, and gabapentin can also be used. Furthermore,
opioid antagonists (naloxone, methyl-naltrexone, alvimopan), which relieve pain by inhibiting the Gs mu receptor,
can be used to treat narcotic bowel syndrome symptoms.
This case is an example of how narcotic bowel syndrome is
often underrecognized, leading to physical suffering and
ﬁnancial burden. A high level of clinical suspicion is
necessary to make a timely diagnosis of narcotic bowel
syndrome.
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